article thumbnail

Delivering on the promise of gene editing

Drug Discovery World

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies.

article thumbnail

New insights into HIV latent cells yield potential cure targets

Drug Discovery World

This technology defines gene expression patterns from rare cells harbouring latent HIV by generating millions of single-cell reaction containers in the form of water-in-oil emulsions, in which messenger RNA capture and virus DNA detection can be performed sequentially while maintaining segregation among cells.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Study proves connection between autism and the microbiome

Drug Discovery World

The computational study In the new study, the research team developed an algorithm to re-analyse 25 previously published datasets containing microbiome and other ‘omic’ information – such as gene expression, immune system response and diet – from both autistic and neurotypical cohorts.

article thumbnail

Epigenetic Editing with CRISPR Might Be Easier Than We Thought

XTalks

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells through epigenetic editing without altering the genetic sequence itself. It’s a great tool for controlling gene expression.”.

DNA 98
article thumbnail

Researchers teach AI to tailor artificial DNA for drug development

Drug Discovery World

Now we have succeeded in designing our own DNA that contains the exact instructions to control the quantity of a specific protein,” said Aleksej Zelezniak. . The AI designs synthetic DNA, where it is easy to modify its regulatory information in the desired direction of gene expression. .

DNA 52
article thumbnail

Nucleome raises £37.5m to shine light on ‘dark genome’

pharmaphorum

The dark genome – a loose term that covers non-coding regions of the genome that are capable of regulating the expression of genes, previously rather inaccurately referred to as junk DNA – is increasingly being explored by biopharma companies for new drug targets. Dr Danuta Jeziorska.

Genome 59
article thumbnail

Biotech founder arrested in US amid murder-for-hire investigation

pharmaphorum

Gümrükcü is a specialist in gene expression profiling in stem cells, and has been working on ways to deliver stem cell transplants to treat cancer without the need for high-dose induction chemotherapy to destroy the patient’s bone marrow. .” ” If convicted, they face mandatory life in prison or the death penalty.